Mark Jeffrey DeLong - 18 May 2021 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Senior Vice President
Signature: /s/ David Watson, attorney-in-fact for Mark Delong
Issuer symbol: APLS
Transactions as of: 18 May 2021
Net transactions value: -$78,960
Form type: 4
Filing time: 19 May 2021, 16:04:09 UTC
Next filing: 16 Jun 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$31,040	+2,000	+21%	$15.52	11,490	18 May 2021	Direct	F1, F2
transaction	APLS	Common Stock	Sale	$110,000	-2,000	-17%	$55.00	9,490	18 May 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-2,000	-4%	$0.000000	48,000	18 May 2021	Common Stock	2,000	$15.52	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise from an established 10B5-1 trading plan.
F2	This amount includes 792 shares from 04/30/2021 ESPP purchase.
F3	This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant date, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.